

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



**華潤醫藥集團有限公司**

**China Resources Pharmaceutical Group Limited**

*(Incorporated in Hong Kong with limited liability)*

**(Stock Code: 3320)**

**VOLUNTARY ANNOUNCEMENT  
SELECTION RESULTS OF  
NATIONAL CENTRALIZED PHARMACEUTICALS  
PROCUREMENT AND  
CENTRALIZED PHARMACEUTICALS PROCUREMENT  
IN THE LEAGUE**

This is a voluntary announcement made by China Resources Pharmaceutical Group Limited (the “**Company**”, and together with its subsidiaries, the “**Group**”).

The Company hereby announces that 3 products of the Group (the “**Products**”) are being selected in the tender for National Centralized Pharmaceuticals Procurement\* (全國藥品集中採購) or the Centralized Pharmaceuticals Procurement in the League\* (聯盟地區藥品集中採購) in the PRC respectively, and the relevant selection results are stated below:

<b>Subsidiary</b>	<b>Category</b>	<b>Specification and Packaging</b>	<b>Pricing Unit</b>	<b>Selected Price (RMB)</b>	<b>Supplying Province</b>
Guangdong China Resources Shunfeng Pharmaceutical Co., Ltd.* (廣東華潤順峰藥業有限公司)	Hydrotalcite Chewable Tablets	0.5g * 24 tablets	Box	7.26/box	Beijing, Zhejiang, Henan, Hubei, Hunan, Tianjin, Guangxi, Chongqing, Guizhou, Tibet, Shaanxi, Qinghai, Hebei, Inner Mongolia, Jilin

Subsidiary	Category	Specification and Packaging	Pricing Unit	Selected Price (RMB)	Supplying Province
Zhejiang China Resources Sanjiu Zhongyi Pharmaceutical Co., Ltd.* (浙江華潤三九眾益製藥有限公司)	Azithromycin Tablets	0.25g * 6 tablets	Box	6.13/box	Anhui, Hubei, Hainan, Sichuan, Yunnan, Inner Mongolia, Shanghai
China Resources Saike Pharmaceutical Co., Ltd.* (華潤賽科藥業有限責任公司)	Terazosin Hydrochloride Tablets	2mg * 14 tablets	Tablet	0.4836/tablet	Jiangsu, Jiangxi, Shandong, Henan, Hunan, Tianjin, Sichuan, Guizhou, Tibet, Gansu, Qinghai, Xinjiang (including the Corps), Inner Mongolia, Jilin, Shanghai

The selected categories of the Group are Hydrotalcite Chewable Tablets, Azithromycin Tablets and Terazosin Hydrochloride Tablets. Subject to the subsequent signing and implementation of procurement agreements, it will be beneficial for the Products to expand their market coverage and sales, enhance their market competitiveness, and have a positive impact on the future operating results of the Group.

Currently, the Group has entered into applicable Memorandum of Selected Categories for National Centralized Pharmaceuticals Procurement\* (《全國藥品集中採購擬中選品種備忘錄》) and Memorandum of Selected Categories for Centralized Pharmaceuticals Procurement in the League\* (《聯盟地區藥品集中採購擬中選品種備忘錄》) with the Joint Procurement Office\* (聯合採購辦公室) in respect of the Products respectively, while uncertainties still remain with the subsequent matters of the Products, including the signing of the procurement agreements. The Company will closely monitor the progress of the matter and will perform its information disclosure obligations in a timely manner.

**Shareholders and potential investors of the Company should exercise caution when dealing in securities of the Company.**

By order of the Board  
**China Resources Pharmaceutical Group Limited**  
**WANG Chuncheng**  
*Chairman*

Shenzhen, 20 January 2020

*As of the date of this announcement, the Board comprises Mr. WANG Chuncheng as chairman and non-executive Director, Mr. HAN Yuewei, Mr. LI Xiangming and Mdm. WENG Jingwen as executive Directors, Mr. YU Zhongliang, Mdm. GUO Wei, Mr. WANG Shouye and Mr. LYU Ruizhi as non-executive Directors and Mdm. SHING Mo Han Yvonne, Mr. KWOK Kin Fun, Mr. FU Tingmei and Mr. ZHANG Kejian as independent non-executive Directors.*

\* *For identification purpose only*